Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 10/2022

11.07.2022 | Original Article

Portal Vein Thrombosis After Venous Reconstruction During Pancreatectomy: Timing and Risks

verfasst von: Alexandra M. Roch, E. Molly Kilbane, Trang Nguyen, Eugene P. Ceppa, Nicholas J. Zyromski, C. Max Schmidt, Attila Nakeeb, Michael G. House

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Numerous studies have shown that portal vein resection during pancreatectomy can help achieve complete tumor clearance and long term-survival. While the safety of vascular resection during pancreatectomy is well documented, the risk of superior mesenteric vein/portal vein (SMV/PV) thrombosis after reconstruction remains unclear. This study aimed to describe the incidence and risk factors of SMV/PV thrombosis after vein reconstruction during pancreatectomy.

Methods

All patients who underwent portal vein resection (PVR) during pancreatectomy (2007–2019) were identified from a single institution prospective clinical database. Demographic and clinical data, operative and pathological findings, and postoperative outcomes were analyzed.

Results

Pancreatectomy with PVR was performed in 220 patients (mean age 65.1 years, male/female ratio 0.96). Thrombosis occurred in 36 (16.4%) patients after a median of 15.5 days [IQR 38.5, 1–786 days]. SMV/PV patency rates were 92.7% and 88.7% at 1 and 3 months, respectively. The rate of SMV/PV thrombosis varied according to SMV/PV reconstruction technique: 12.8% after venorrhaphy, 13.2% end-to-end anastomosis, 22.6% autologous vein, and 83.3% synthetic graft interposition (p < 0.0001). SMV/PV thrombosis was associated with increased 90-day mortality (16.7% vs 4.9%, p = 0.02) and overall 30-day complication rate (69.4% vs 42.9%, p = 0.006). Pancreatectomy type, neoadjuvant chemoradiation, pathologic tumor venous invasion, resection margin status, and manner of perioperative anticoagulation did not influence the incidence of PV thrombosis. SMV/PV thrombosis was associated with a nearly 5-times increased risk of postoperative sepsis after pancreatectomy.

Conclusion

Portal vein thrombosis developed in 16% of patients who underwent pancreatectomy with PVR at a median of 15 days. PVR with synthetic interposition graft carries the highest risk for thrombosis.
Literatur
1.
Zurück zum Zitat Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg. 1996;224(3):342-9.CrossRef Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg. 1996;224(3):342-9.CrossRef
2.
Zurück zum Zitat Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery 1973; 73:307–20.PubMed Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery 1973; 73:307–20.PubMed
3.
Zurück zum Zitat Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 1992; 215:231–6.CrossRef Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 1992; 215:231–6.CrossRef
4.
Zurück zum Zitat Roch AM, House MG, Cioffi J, Ceppa EP, Zyromski NJ, Nakeeb A, Schmidt CM. Significance of Portal Vein Invasion and Extent of Invasion in Patients Undergoing Pancreatoduodenectomy for Pancreatic Adenocarcinoma. J Gastrointest Surg. 2016 Mar;20(3):479-87.CrossRef Roch AM, House MG, Cioffi J, Ceppa EP, Zyromski NJ, Nakeeb A, Schmidt CM. Significance of Portal Vein Invasion and Extent of Invasion in Patients Undergoing Pancreatoduodenectomy for Pancreatic Adenocarcinoma. J Gastrointest Surg. 2016 Mar;20(3):479-87.CrossRef
5.
Zurück zum Zitat Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 2012; 36:884–91.CrossRef Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 2012; 36:884–91.CrossRef
6.
Zurück zum Zitat Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8(8):935-49.CrossRef Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8(8):935-49.CrossRef
7.
Zurück zum Zitat Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ, Lee JE, Evans DB. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996 Feb;223(2):154-62. Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR, El-Naggar AK, Fenoglio CJ, Lee JE, Evans DB. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996 Feb;223(2):154-62.
8.
Zurück zum Zitat Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN et al Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721–33.CrossRef Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN et al Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721–33.CrossRef
9.
Zurück zum Zitat Ghaneh P, Kleeff J, Halloran CM et al. European Study Group for Pancreatic Cancer. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg 2019 Mar;269(3):520-9.CrossRef Ghaneh P, Kleeff J, Halloran CM et al. European Study Group for Pancreatic Cancer. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg 2019 Mar;269(3):520-9.CrossRef
10.
Zurück zum Zitat Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1736-44.CrossRef Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1736-44.CrossRef
11.
Zurück zum Zitat Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-10.CrossRef Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-10.CrossRef
12.
Zurück zum Zitat Howard TJ, Villanustre N, Moore SA, DeWitt J, LeBlanc J, Maglinte D et al. Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head. J Gastrointest Surg 2003; 7: 1089–1095.CrossRef Howard TJ, Villanustre N, Moore SA, DeWitt J, LeBlanc J, Maglinte D et al. Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head. J Gastrointest Surg 2003; 7: 1089–1095.CrossRef
13.
Zurück zum Zitat Siriwardana H. P. P. and Siriwardena A. K. Systematic review of outcome of synchronous portal–superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006; 93: 662–73.CrossRef Siriwardana H. P. P. and Siriwardena A. K. Systematic review of outcome of synchronous portal–superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 2006; 93: 662–73.CrossRef
14.
Zurück zum Zitat Guilbaud T, Turrini O, Lemoine C, Le Treut YP, Ouaissi M, Moutardier V, Delpero JR. Venous Resection in Pancreatic Ductal Adenocarcinoma: Impact of Surgical Experience on Early Postoperative Courses. Anticancer Research Aug 2017;37 (8):4205-13PubMed Guilbaud T, Turrini O, Lemoine C, Le Treut YP, Ouaissi M, Moutardier V, Delpero JR. Venous Resection in Pancreatic Ductal Adenocarcinoma: Impact of Surgical Experience on Early Postoperative Courses. Anticancer Research Aug 2017;37 (8):4205-13PubMed
15.
Zurück zum Zitat Gao W, Dai X, Dai C et al. Comparison of patency rates and clinical impact of different reconstruction methods following portal/superior mesenteric vein resection during pancreatectomy. Pancreatology 2016;16(6):1113–23.CrossRef Gao W, Dai X, Dai C et al. Comparison of patency rates and clinical impact of different reconstruction methods following portal/superior mesenteric vein resection during pancreatectomy. Pancreatology 2016;16(6):1113–23.CrossRef
16.
Zurück zum Zitat Dua MM, Tran TB, Klausner J et al. Pancreatectomy with vein reconstruction: technique matters. HPB 2015;17(9):824–31.CrossRef Dua MM, Tran TB, Klausner J et al. Pancreatectomy with vein reconstruction: technique matters. HPB 2015;17(9):824–31.CrossRef
17.
Zurück zum Zitat Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006; 10:1106-15.CrossRef Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006; 10:1106-15.CrossRef
18.
Zurück zum Zitat Capussotti L, Massucco P, Ribero D, Viganò L, Muratore A, Calgaro M. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003; 138:1316-22.CrossRef Capussotti L, Massucco P, Ribero D, Viganò L, Muratore A, Calgaro M. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003; 138:1316-22.CrossRef
19.
Zurück zum Zitat Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85:611-7.CrossRef Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85:611-7.CrossRef
20.
Zurück zum Zitat Kang MJ, Jang JY, Chang YR, Jung W, Kim SW. Portal vein patency after pancreatoduodenectomy for periampullary cancer. Br J Surg 2015; 102:77-84.CrossRef Kang MJ, Jang JY, Chang YR, Jung W, Kim SW. Portal vein patency after pancreatoduodenectomy for periampullary cancer. Br J Surg 2015; 102:77-84.CrossRef
21.
Zurück zum Zitat Glebova NO, Hicks CW, Piazza KM, Abularrage CJ, Cameron AM, Schulick RD, Wolfgang CL, Black JH III. Technical risk factors for portal vein reconstruction thrombosis in pancreatic resection. J Vasc Surg. 2015 Aug; 62(2):424-33.CrossRef Glebova NO, Hicks CW, Piazza KM, Abularrage CJ, Cameron AM, Schulick RD, Wolfgang CL, Black JH III. Technical risk factors for portal vein reconstruction thrombosis in pancreatic resection. J Vasc Surg. 2015 Aug; 62(2):424-33.CrossRef
22.
Zurück zum Zitat Delpero JR, Sauvanet A. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. Front Oncol. 2020; 10:40.CrossRef Delpero JR, Sauvanet A. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. Front Oncol. 2020; 10:40.CrossRef
23.
Zurück zum Zitat Ouaissi M, Sielezneff I, Pirro N, et al. Therapeutic anticoagulant does not modify thromboses rate vein after venous reconstruction following pancreaticoduodenectomy. Gastroenterol Res Pract. 2008;896320. Ouaissi M, Sielezneff I, Pirro N, et al. Therapeutic anticoagulant does not modify thromboses rate vein after venous reconstruction following pancreaticoduodenectomy. Gastroenterol Res Pract. 2008;896320.
24.
Zurück zum Zitat Smoot RL, Christein JD, Farnell MB. Durability of portal venous reconstruction following resection during pancreaticoduodenectomy. J Gastrointest Surg 2006; 10:1371–5.CrossRef Smoot RL, Christein JD, Farnell MB. Durability of portal venous reconstruction following resection during pancreaticoduodenectomy. J Gastrointest Surg 2006; 10:1371–5.CrossRef
25.
Zurück zum Zitat Stauffer JA, Dougherty MK, Kim GP, Nguyen JH. Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy. Br J Surg 2009; 96:247–52.CrossRef Stauffer JA, Dougherty MK, Kim GP, Nguyen JH. Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy. Br J Surg 2009; 96:247–52.CrossRef
26.
Zurück zum Zitat Chu CK, Farnell MB, Nguyen JH, et al. Prosthetic graft reconstruction after portal vein resection in pancreaticoduodenectomy: a multicenter analysis. J Am Coll Surg. 2010; 211:316–24.CrossRef Chu CK, Farnell MB, Nguyen JH, et al. Prosthetic graft reconstruction after portal vein resection in pancreaticoduodenectomy: a multicenter analysis. J Am Coll Surg. 2010; 211:316–24.CrossRef
27.
Zurück zum Zitat Sgroi MD, Narayan RR, Lane JS, et al. Vascular reconstruction plays an important role in the treatment of pancreatic adenocarcinoma. J Vasc Surg 2015; 61:475–80.CrossRef Sgroi MD, Narayan RR, Lane JS, et al. Vascular reconstruction plays an important role in the treatment of pancreatic adenocarcinoma. J Vasc Surg 2015; 61:475–80.CrossRef
28.
Zurück zum Zitat Chandrasegaram MD, Eslick GD, Lee W, Brooke-Smith ME, Padbury R, Worthley CS et al. Anticoagulation policy after venous resection with a pancreatectomy: a systematic review. HPB 2014; 16:691–8.CrossRef Chandrasegaram MD, Eslick GD, Lee W, Brooke-Smith ME, Padbury R, Worthley CS et al. Anticoagulation policy after venous resection with a pancreatectomy: a systematic review. HPB 2014; 16:691–8.CrossRef
29.
Zurück zum Zitat Smoot RL, Christein JD, Farnell MB. An innovative option for venous reconstruction after pancreaticoduodenectomy: the left renal vein. J Gastrointest Surg 2007; 11:425-31.CrossRef Smoot RL, Christein JD, Farnell MB. An innovative option for venous reconstruction after pancreaticoduodenectomy: the left renal vein. J Gastrointest Surg 2007; 11:425-31.CrossRef
30.
Zurück zum Zitat Wang F, Arianayagam R, Gill A, Puttaswamy V, Neale M, Gananadha S et al. Grafts for mesenterico-portal vein resections can be avoided during pancreaticoduodenectomy. J Am Coll Surg 2012; 215:569–79.CrossRef Wang F, Arianayagam R, Gill A, Puttaswamy V, Neale M, Gananadha S et al. Grafts for mesenterico-portal vein resections can be avoided during pancreaticoduodenectomy. J Am Coll Surg 2012; 215:569–79.CrossRef
31.
Zurück zum Zitat Roch AM, Maatman TK, Carr RA, Colgate CL, Ceppa EP, House MG, Lopes J, Nakeeb A, Schmidt CM, Zyromski NJ. Venous Thromboembolism in Necrotizing Pancreatitis: An Underappreciated Risk. J Gastrointest Surg. 2019 Dec;23(12):2430-8.CrossRef Roch AM, Maatman TK, Carr RA, Colgate CL, Ceppa EP, House MG, Lopes J, Nakeeb A, Schmidt CM, Zyromski NJ. Venous Thromboembolism in Necrotizing Pancreatitis: An Underappreciated Risk. J Gastrointest Surg. 2019 Dec;23(12):2430-8.CrossRef
32.
Zurück zum Zitat Clark W, Silva M, Donn N, Luberice K, Humphries LA, Paul H, et al. Targeting early deaths following pancreaticoduodenectomy to improve survival. J Gastrointest Surg 2012; 16:1869–74.CrossRef Clark W, Silva M, Donn N, Luberice K, Humphries LA, Paul H, et al. Targeting early deaths following pancreaticoduodenectomy to improve survival. J Gastrointest Surg 2012; 16:1869–74.CrossRef
Metadaten
Titel
Portal Vein Thrombosis After Venous Reconstruction During Pancreatectomy: Timing and Risks
verfasst von
Alexandra M. Roch
E. Molly Kilbane
Trang Nguyen
Eugene P. Ceppa
Nicholas J. Zyromski
C. Max Schmidt
Attila Nakeeb
Michael G. House
Publikationsdatum
11.07.2022
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 10/2022
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-022-05401-1

Weitere Artikel der Ausgabe 10/2022

Journal of Gastrointestinal Surgery 10/2022 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.